Exicure (NASDAQ:XCUR – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Institutional & Insider Ownership
42.8% of Exicure shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Exicure and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| Aurinia Pharmaceuticals | 100.84% | 26.11% | 19.89% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Exicure and Aurinia Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| Aurinia Pharmaceuticals | 0 | 3 | 3 | 1 | 2.71 |
Aurinia Pharmaceuticals has a consensus target price of $17.75, suggesting a potential upside of 6.61%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than Exicure.
Volatility & Risk
Exicure has a beta of 3.64, meaning that its share price is 264% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Valuation and Earnings
This table compares Exicure and Aurinia Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 13.23 | -$4.95 million | ($1.32) | -0.77 |
| Aurinia Pharmaceuticals | $283.05 million | 7.83 | $287.20 million | $2.29 | 7.27 |
Aurinia Pharmaceuticals has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Exicure on 10 of the 14 factors compared between the two stocks.
About Exicure
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
